Results 171 to 180 of about 687,197 (297)

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

Zoonotic relevance of multidrug-resistant bacteria in parrots with respiratory illness. [PDF]

open access: yesVet Res Commun
Samir A   +8 more
europepmc   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Respiratory illness in children [PDF]

open access: yesThe Journal of Pediatrics, 1995
openaire   +2 more sources

Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe Acute respiratory illness cases in selected health facilities in Ethiopia. [PDF]

open access: yesFront Public Health
Tayachew A   +14 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix   +4 more
wiley   +1 more source

Employing AI tools to predict features for dental care use in the United States during the global respiratory illness outbreak. [PDF]

open access: yesFront Public Health
Zanwar PP   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy